233 episodes

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

BioCentury This Week BioCentury

    • Science
    • 5.0 • 11 Ratings

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

    Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves

    Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves

    Vertex Pharmaceuticals' acquisition of Alpine Immune Sciences will bolster a growing kidney disease franchise that could help diversify Vertex’s business beyond its blockbuster cystic fibrosis franchise. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what attracted Vertex to Alpine and why it believes its newly acquired therapy can outshine others for IgA nephropathy. The editors discuss how Goldman Sachs aims to scale private biotechs via its venture strategy and the likely key factors for CMS as it determines prices for the first cohort of drugs in Medicare drug price negotiations under the Inflation Reduction Act. They also preview BioCentury’s first R&D conference — Grand Rounds — which will focus on the biotech industry’s interface with academia, bringing together decision-makers and the next innovators in Nashville, Sept. 9-11. This week’s podcast is sponsored by Jeito Capital. 

    • 22 min
    Ep. 225 - 2Q Markets Preview & AACR Takeaways

    Ep. 225 - 2Q Markets Preview & AACR Takeaways

    M&A has been driving a recovery for biotech, with $62 billion in takeouts in the past six months restocking specialist investors’ coffers for their next wave of investments. On the latest BioCentury This Week podcast, BioCentury’s editors assess the state of the public markets heading into the second quarter, including the outsize role PIPEs have had in financing industry’s comeback. They also discuss their takeaways from analyzing nearly 7,000 abstracts from the American Association for Cancer Research and the editors’ insights on why degrader-antibody conjugates are emerging as the next contenders to build on the success of the antibody-drug conjugates paradigm. Editor in Chief Simone Fishburn also previews Grand Rounds, BioCentury’s first R&D conference, which will focus on the biotech industry’s interface with academia, bringing together decision-makers and the next innovators in Nashville Sept. 9-11. To learn more about BioCentury Grand Rounds and opportunities to present, see the conference website. This week’s podcast is sponsored by Jeito Capital. 

    • 21 min
    Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

    Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

    Upcoming catalysts could drive value creation at NASDAQ’s newest biotech, Boundless Bio, after it stumbled in its trading debut last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Boundless’ IPO in the context of the current market for fresh paper and profile the “sweat equity” model of Avalon, the VC firm led by Jay Lichter. Turning to Washington, BioCentury’s editors assess possible outcomes for the Supreme Court case on abortion drug mifepristone, and why the court’s pending decision could safeguard FDA from judicial second-guessing. The team also analyzes the agency’s first ever complete response letter for lack of confirmatory trial enrollment.  This week’s podcast is sponsored by Jeito Capital. 

    • 21 min
    Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

    Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

    Bills seeking to rein in Chinese CDMOs and genomics companies will deal a massive blow to biotech companies, if passed in their current form, according to results from an industry survey conducted by BioCentury. On The latest BioCentury This Week podcast, BioCentury’s editors discuss results from the survey, including responses that underscore executives’ concerns that the legislation would cause delays in drug development and a majority’s displeasure with BIO’s about-face to support the measures.
    They also discuss takeaways from Editor in Chief Simone Fishburn’s conversation on The BioCentury Show with Atlas Venture’s Bruce Booth, and lessons from Orchard Therapeutics on what it takes to get FDA’s approval for an ultrarare disease drug.
    For BioCentury’s complete coverage of the Biosecure Act and similar legislation in Senate, visit the Hot Topics page for the topic

    • 28 min
    Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts

    Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts

    Putting patients at center stage is at the core of John Crowley’s vision for BIO as he begins his tenure leading the biotech trade group. On the latest BioCentury This Week podcast. Washington Editor Steve Usdin details Crowley’s plans to revitalize BIO at a time when effective representation in Washington is more important than ever.
    BioCentury’s editors also discuss FDA’s landmark approval of Madrigal's liver disease drug and a decision by FDA’s Oncologic Drugs Advisory Committee to support a pair of BCMA-directed CAR T cell therapies in earlier lines to treat multiple myeloma, and what’s needed to help avoid deaths during the period while patient wait for the CAR T cells to be produced.

    • 20 min
    Ep. 221 - China Biocontroversy, Plus: Diversity Matters

    Ep. 221 - China Biocontroversy, Plus: Diversity Matters

    A congressional committee meeting last week on biotech and national security provided a glimmer of hope that lawmakers could be persuaded to consider taking steps to bolster the U.S. bioeconomy, BioCentury Washington Editor Steve Usdin explains why the at times cartoonish spectacle of lawmakers pushing anti-China biotech bills highlights the need for scientists and entrepreneurs to build relationships in Washington.
    Plus: Editor in Chief Simone Fishburn argues that the future of diversity should not be bound up in the fate of DEI. And BioCentury's editors discuss the pivotal trial setback for Amylyx in ALS and what may be on FDA’s agenda as is schedules an advisory meeting for Lilly's Alzheimer's therapy donanemab.

    • 31 min

Customer Reviews

5.0 out of 5
11 Ratings

11 Ratings

Pretty Kitty 2 ,

Simone Fishburn!!!!

Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Radiolab
WNYC Studios
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson
Science Vs
Spotify Studios

You Might Also Like

The Readout Loud
STAT
Business Of Biotech
Matt Pillar
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more
The Long Run with Luke Timmerman
Timmerman Report
Raising Health
Andreessen Horowitz
Biotech 2050 Podcast
Biotech 2050